COMP <GO>

RNTX vs SPRO // FORWARD P/E MULTIPLE

Rein Therapeutics Inc. (NASDAQ) VS. Spero Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RNTX 1 — SPRO 3

■ METRIC PARITY

LAST: $0.67 (-7.79%) • MKT CAP: $62.7M

forward-pe

—

LAST: $1.06 (-4.50%) • MKT CAP: $64.6M

forward-pe

6.3x

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RNTX VS. SPRO) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	RNTX	SPRO	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	26.60%	-61.60	SPRO	/roic <GO>
EV/EBITDA & P/E Valuation	—	5.1x	—	TIE	/valuation <GO>
Free Cash Flow Yield	—	-19.53%	—	TIE	/fcf-yield <GO>
Operating Margin	—	50.20%	—	TIE	/operating-margins <GO>
Net Profit Margin	—	68.00%	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	180.00%	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	0.20	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	2/9	5/9	-3.00	SPRO	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	47.4	41.2	+6.16	RNTX	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple ACTIVE	—	6.3x	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$62.7M	$64.6M	-$2.0M	SPRO	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	RNTX REV	SPRO REV	RNTX GROSS %	SPRO GROSS %	RNTX FCF	SPRO FCF
FY 2025	$0	$12.6M	—	—	-$19.4M	-$12.6M
FY 2024	$0	$371.0K	—	—	-$22.3M	-$23.4M
FY 2023	$0	$933.0K	—	—	-$19.8M	-$33.0M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

RNTX // BETA —

SPRO // BETA —